Sarepta Therapeutics Stock Gross Profit

SRPT Stock

USD 110.50 0.36 0.32%

Sarepta Therapeutics fundamentals help investors to digest information that contributes to Sarepta Therapeutics' financial success or failures. It also enables traders to predict the movement of Sarepta Stock. The fundamental analysis module provides a way to measure Sarepta Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sarepta Therapeutics stock.

	Last Reported	Projected for Next Year
Gross Profit	1.1 B	1.1 B
Gross Profit Margin	0.88	0.92

Gross Profit is likely to gain to about 1.1 B in 2024. Gross Profit Margin is likely to gain to 0.92 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sarepta Therapeutics Company Gross Profit Analysis

Sarepta Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Sarepta Therapeutics Gross Profit

(78.07 M)

Most of Sarepta Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sarepta Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Sarepta Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for Sarepta Therapeutics is extremely important. It helps to project a fair market value of Sarepta Stock properly, considering its historical fundamentals such as Gross Profit. Since Sarepta Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sarepta Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sarepta Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Net Receivables	Current Deferred Revenue	Long Term Debt	Short Term Debt	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.79	0.34	-0.97	0.9	0.75	0.98	1.0	0.78	-0.3	0.97	0.86	0.84	0.97	0.76	0.63	0.99	0.99	0.93	0.96	0.05	0.92	0.88
Total Stockholder Equity	0.79		0.11	-0.71	0.63	0.61	0.64	0.8	0.76	-0.38	0.69	0.57	0.42	0.67	0.73	0.93	0.76	0.81	0.81	0.65	0.37	0.56	0.56
Net Debt	0.34	0.11		-0.5	0.58	0.82	0.39	0.31	0.56	-0.01	0.53	0.69	0.1	0.39	-0.1	-0.19	0.4	0.41	0.36	0.35	-0.26	0.17	0.51
Retained Earnings	-0.97	-0.71	-0.5		-0.95	-0.81	-0.97	-0.96	-0.82	0.33	-0.99	-0.93	-0.78	-0.96	-0.66	-0.5	-0.97	-0.98	-0.9	-0.96	0.08	-0.87	-0.94
Accounts Payable	0.9	0.63	0.58	-0.95		0.81	0.91	0.88	0.87	-0.26	0.97	0.96	0.71	0.86	0.64	0.36	0.92	0.92	0.86	0.9	-0.19	0.82	0.91
Short Term Investments	0.75	0.61	0.82	-0.81	0.81		0.72	0.74	0.79	-0.24	0.82	0.85	0.44	0.74	0.35	0.35	0.76	0.79	0.73	0.68	0.05	0.54	0.71
Total Liab	0.98	0.64	0.39	-0.97	0.91	0.72		0.97	0.71	-0.24	0.97	0.88	0.9	0.98	0.7	0.48	0.98	0.95	0.89	0.97	-0.06	0.95	0.91
Total Current Assets	1.0	0.8	0.31	-0.96	0.88	0.74	0.97		0.76	-0.31	0.95	0.84	0.84	0.97	0.76	0.66	0.99	0.98	0.92	0.94	0.08	0.91	0.86
Intangible Assets	0.78	0.76	0.56	-0.82	0.87	0.79	0.71	0.76		-0.35	0.82	0.88	0.44	0.67	0.6	0.47	0.8	0.83	0.72	0.72	-0.18	0.6	0.78
Common Stock	-0.3	-0.38	-0.01	0.33	-0.26	-0.24	-0.24	-0.31	-0.35		-0.27	-0.19	-0.19	-0.25	-0.19	-0.36	-0.25	-0.33	-0.26	-0.22	-0.08	-0.2	-0.19
Property Plant Equipment	0.97	0.69	0.53	-0.99	0.97	0.82	0.97	0.95	0.82	-0.27		0.94	0.79	0.95	0.67	0.47	0.97	0.98	0.92	0.96	-0.07	0.88	0.93
Net Receivables	0.86	0.57	0.69	-0.93	0.96	0.85	0.88	0.84	0.88	-0.19	0.94		0.65	0.84	0.56	0.27	0.9	0.89	0.8	0.88	-0.26	0.77	0.94
Current Deferred Revenue	0.84	0.42	0.1	-0.78	0.71	0.44	0.9	0.84	0.44	-0.19	0.79	0.65		0.85	0.73	0.35	0.81	0.76	0.68	0.86	-0.05	0.97	0.74
Long Term Debt	0.97	0.67	0.39	-0.96	0.86	0.74	0.98	0.97	0.67	-0.25	0.95	0.84	0.85		0.64	0.54	0.97	0.95	0.89	0.94	0.0	0.9	0.88
Short Term Debt	0.76	0.73	-0.1	-0.66	0.64	0.35	0.7	0.76	0.6	-0.19	0.67	0.56	0.73	0.64		0.65	0.73	0.72	0.73	0.77	0.26	0.82	0.61
Net Tangible Assets	0.63	0.93	-0.19	-0.5	0.36	0.35	0.48	0.66	0.47	-0.36	0.47	0.27	0.35	0.54	0.65		0.58	0.63	0.68	0.47	0.57	0.43	0.3
Long Term Debt Total	0.99	0.76	0.4	-0.97	0.92	0.76	0.98	0.99	0.8	-0.25	0.97	0.9	0.81	0.97	0.73	0.58		0.98	0.92	0.96	-0.04	0.9	0.91
Capital Surpluse	0.99	0.81	0.41	-0.98	0.92	0.79	0.95	0.98	0.83	-0.33	0.98	0.89	0.76	0.95	0.72	0.63	0.98		0.94	0.94	0.03	0.86	0.89
Short Long Term Debt	0.93	0.81	0.36	-0.9	0.86	0.73	0.89	0.92	0.72	-0.26	0.92	0.8	0.68	0.89	0.73	0.68	0.92	0.94		0.9	0.26	0.8	0.81
Net Invested Capital	0.96	0.65	0.35	-0.96	0.9	0.68	0.97	0.94	0.72	-0.22	0.96	0.88	0.86	0.94	0.77	0.47	0.96	0.94	0.9		-0.03	0.95	0.95
Long Term Investments	0.05	0.37	-0.26	0.08	-0.19	0.05	-0.06	0.08	-0.18	-0.08	-0.07	-0.26	-0.05	0.0	0.26	0.57	-0.04	0.03	0.26	-0.03		-0.05	-0.26
Net Working Capital	0.92	0.56	0.17	-0.87	0.82	0.54	0.95	0.91	0.6	-0.2	0.88	0.77	0.97	0.9	0.82	0.43	0.9	0.86	0.8	0.95	-0.05		0.85
Capital Stock	0.88	0.56	0.51	-0.94	0.91	0.71	0.91	0.86	0.78	-0.19	0.93	0.94	0.74	0.88	0.61	0.3	0.91	0.89	0.81	0.95	-0.26	0.85

Click cells to compare fundamentals

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict Sarepta Therapeutics

Gross Profit Over Time

According to the company disclosure, Sarepta Therapeutics reported (78.07 Million) of gross profit. This is 103.48% lower than that of the Biotechnology sector and 108.21% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.29% higher than that of the company.

Sarepta Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sarepta Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sarepta Therapeutics could also be used in its relative valuation, which is a method of valuing Sarepta Therapeutics by comparing valuation metrics of similar companies.

Sarepta Therapeutics is currently under evaluation in gross profit category among its peers.

Sarepta Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sarepta Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sarepta Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Sarepta Fundamentals

	Return On Equity	0.12
	Return On Asset	0.0151
	Profit Margin	0.07 %
	Operating Margin	0.05 %
	Current Valuation	10.79 B
	Shares Outstanding	95.52 M
	Shares Owned By Insiders	4.37 %
	Shares Owned By Institutions	91.92 %
	Number Of Shares Shorted	5.6 M
	Price To Earning	(20.43) X
	Price To Book	8.67 X
	Price To Sales	6.46 X
	Revenue	1.24 B
	Gross Profit	(78.07 M)
	EBITDA	(439.2 M)
	Net Income	(535.98 M)
	Cash And Equivalents	2.07 B
	Cash Per Share	23.61 X
	Total Debt	1.4 B
	Debt To Equity	3.72 %
	Current Ratio	4.36 X
	Book Value Per Share	12.79 X
	Cash Flow From Operations	(500.99 M)
	Short Ratio	7.15 X
	Earnings Per Share	1.54 X
	Price To Earnings To Growth	159.25 X
	Target Price	189.62
	Number Of Employees	1.31 K
	Beta	0.8
	Market Capitalization	10.59 B
	Total Asset	3.26 B
	Retained Earnings	(4.45 B)
	Working Capital	1.93 B
	Current Asset	434.74 M
	Current Liabilities	64.93 M
	Net Asset	3.26 B

About Sarepta Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sarepta Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sarepta Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sarepta Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC